ClinicalTrials.gov record
Completed Phase 1 Interventional

3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome

ClinicalTrials.gov ID: NCT00077558

Public ClinicalTrials.gov record NCT00077558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Trial Of Sequential Administration Of Triapine (3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone) Followed By Fludarabine In Adults With Relapsed And Refractory Leukemias And Myelodysplasias

Study identification

NCT ID
NCT00077558
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • fludarabine phosphate Drug
  • triapine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2003
Primary completion
Not listed
Completion
Not listed
Last update posted
Mar 9, 2010

Started 2004

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Blood and Marrow Transplant Group of Georgia Atlanta Georgia 30342-4777
Greenebaum Cancer Center at University of Maryland Medical Center Baltimore Maryland 21201
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland 21231
M.D. Anderson Cancer Center at University of Texas Houston Texas 77030-4095

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00077558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 9, 2010 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00077558 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →